RAPLIXA

This brand name is authorized in Estonia, Lithuania

Active ingredients

The drug RAPLIXA contains a combination of these active pharmaceutical ingredients (APIs):

1 Human fibrinogen UNII N94833051K - FIBRINOGEN HUMAN

Human fibrinogen (coagulation factor I), in the presence of thrombin, activated coagulation factor XIII (F XIIIa) and calcium ions is converted into a stable and elastic three-dimensional fibrin haemostatic clot. The administration of human fibrinogen concentrate provides an increase in plasma fibrinogen level and can temporarily correct the coagulation defect of patients with fibrinogen deficiency. Read about Human fibrinogen

2 Thrombin UNII 6K15ABL77G - HUMAN THROMBIN

Read about Thrombin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
B02BC30	Combinations	B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BC Local hemostatics
Discover more medicines within B02BC30

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1680825, 1680836, 1680847
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1076030, 1076031, 1076032